All News argenx SE

Equities

ARGX

NL0010832176

Real-time Euronext Bruxelles Other stock markets 03:58:31 2024-04-30 EDT			5-day change	1st Jan Change
349.2 ^EUR	+0.20%		+0.06%	+1.72%

04-17	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT
04-16	Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	04-17	MT
Argenx : argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease	04-16	PU
Argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease	04-16	GL
Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	04-16	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	04-04	MT
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey	03-28	AQ
Argenx : argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease	03-27	PU
Argenx : argenx Announces Annual General Meeting of Shareholders on May 7, 2024	03-27	PU
Argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease	03-27	GL
Argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease	03-27	CI
Argenx Announces Annual General Meeting of Shareholders on May 7, 2024	03-26	GL
Scotiabank Raises Price Target on Argenx SE to $408 From $402, Maintains Sector Perform Rating	03-26	MT
Argenx Gets Japanese Regulator's Approval for Intravenous Use of Vyvgart in Primary Immune Thrombocytopenia	03-26	MT
Argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia	03-26	GL
Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia	03-26	CI
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	03-21	MT
US Futures, European Stocks Rise After Fed Maintains Outlook	03-21	DJ
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	03-13	MT
Argenx : argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting	03-08	PU
Argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting	03-07	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News argenx SE

Equities

ARGX

NL0010832176

All News

Filters